FDA — authorised 13 June 2019
- Application: BLA761073
- Marketing authorisation holder: AMGEN INC
- Local brand name: KANJINTI
- Indication: VIAL — MULTIDOSE
- Status: approved
🇺🇸 KANJINTI in United States
FDA authorised KANJINTI on 13 June 2019
Marketing authorisation
KANJINTI in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Other approved in United States
Frequently asked questions
Is KANJINTI approved in United States?
Yes. FDA authorised it on 13 June 2019.
Who is the marketing authorisation holder for KANJINTI in United States?
AMGEN INC holds the US marketing authorisation.